Chronic kidney disease (CKD) refers to a set of heterogenous disorders that affect the structure and function of the kidneys. The CKD drug market comprises a wide variety of antihypertensive agents and SGLT-2 inhibitors, which are intended to delay the progression of kidney damage. RAAS inhibitors are standard-of-care therapy for CKD. In 2021, AstraZeneca’s SGLT-2 inhibitor Farxiga (dapagliflozin) became the first SGLT-2 drug to demonstrate a renoprotective effect in a dedicated renal outcomes trial and to receive formal label approval from the FDA for the treatment of CKD irrespective of the presence or absence of diabetes. Other SGLT-2 inhibitors such as Eli Lilly’s Jardiance (empagliflozin) and Johnson & Johnson’s Invokana (canagliflozin) also demonstrated renoprotective benefits in diabetic patients with CKD in the EMPA-REG and CREDENCE trials. This drug class is heavily prescribed to patients with diabetic kidney disease and is set to play an increasingly important role in CKD treatment. Bayer’s Kerendia (finerenone), a mineralocorticoid receptor antagonist, has shown substantial renal benefits in CKD patients with diabetes; clinical trials of finerenone in nondiabetic CKD patients are ongoing. Supported by insights from thought leaders, we analyze the challenges associated with marketing drugs to treat an increasingly dynamic and complex disease.
Does the inclusion of cardiovascular endpoints in clinical trials of select CKD therapies confer a competitive advantage once the therapies become commercially available?
Are SGLT-2 inhibitors set to become the standard-of-care therapy for CKD?
How do KOLs view the advantages and disadvantages of current therapies and the mechanisms of action of emerging therapies?
What are the greatest unmet needs in CKD? Which drugs in development will fulfill these unmet needs?
What market access and reimbursement challenges will the emerging therapies face in the G7? How will these challenges influence their uptake?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.